Organogenesis/$ORGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Employees
869
Headquarters
Website
Organogenesis Metrics
BasicAdvanced
$540M
-
-$0.12
1.69
-
Price and volume
Market cap
$540M
Beta
1.69
52-week high
$6.71
52-week low
$2.61
Average daily volume
669K
Financial strength
Current ratio
3.952
Quick ratio
2.938
Long term debt to equity
8.595
Total debt to equity
11.3
Interest coverage (TTM)
-35.48%
Profitability
EBITDA (TTM)
3.166
Gross margin (TTM)
74.58%
Net profit margin (TTM)
-1.92%
Operating margin (TTM)
-3.39%
Effective tax rate (TTM)
61.79%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-2.01%
Return on equity (TTM)
-2.64%
Valuation
Price to revenue (TTM)
1.278
Price to book
2.32
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-11.838
Free cash flow yield (TTM)
-8.45%
Free cash flow per share (TTM)
-0.36
Growth
Revenue change (TTM)
-4.21%
Earnings per share change (TTM)
-1.33%
3-year revenue growth (CAGR)
-2.27%
3-year earnings per share growth (CAGR)
-38.45%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Bulls say / Bears say
Surgical & Sports Medicine product revenue grew 16% year-over-year to $8.1 million in Q2 2025, demonstrating successful diversification into higher-margin segments.
Net loss narrowed to $9.4 million in Q2 2025 from $17.0 million in Q2 2024, reflecting improved operational leverage and cost management.
As of March 31, 2025, the company held $110.5 million in cash with no debt, providing ample runway for R&D investment and pipeline advancement
Total net product revenue for Q2 2025 fell 23% year-over-year to $100.8 million, underscoring persistent volume pressures in the core business.
Advanced Wound Care net product revenue declined 25% to $92.7 million in Q2 2025, reflecting ongoing reimbursement headwinds and market disruption.
Adjusted EBITDA swung to a loss of $3.6 million in Q2 2025, down from income of $15.6 million a year earlier, highlighting margin compression
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Organogenesis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $540M as of October 27, 2025.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of October 27, 2025.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.